Phase 1 Trial of LVGN7409 (CD40 Agonist Antibody) as Single Agent and Combination Therapies in Advanced or Metastatic Malignancy

Cancer shared this article with you from Inoreader Phase 1 Trial of LVGN7409 (CD40 Agonist Antibody) as Single Agent and Combination Therapies in Advanced or Metastatic Malignancy Via MedWorm Cancer & Oncology Clinical Trials Condition:   Cancer Intervention:   Biological: LVGN7409 Sponsor:   Lyvgen Biopharma Holdings Limited Not yet recruiting (Source: ClinicalTrials.gov) View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.